DuPont (DD) Q4 2025 earnings review
Smaller DuPont Delivers Efficiency, But Volumes Stall
In its first quarter as a streamlined company following the Qnity (Electronics) spin-off, DuPont delivered an earnings beat despite stagnant top-line demand. While Adjusted EPS grew 18% YoY to $0.46, Net Sales were flat ($1.7B) and organic sales dipped 1% due to ongoing weakness in construction markets and a timing shift of orders into Q3. The story was margin preservation: Operating EBITDA margin expanded 80 bps to 24.2%, driven by cost productivity that offset volume declines. Guidance for FY26 suggests a pivot to growth, targeting ~3% organic expansion.
🐂 Bull Case
Despite a 4% organic sales decline in Diversified Industrials, segment Operating EBITDA grew 2% and margins expanded 110 bps. This confirms the 'New DuPont' can extract profit growth through cost productivity even in a low-volume environment.
The core growth engine, Healthcare & Water Technologies, delivered 3% organic growth (4% reported) amidst a macro slowdown, driven by medical packaging and industrial water demand. This segment now comprises nearly half of the portfolio.
🐻 Bear Case
Building Technologies (part of Diversified Industrials) was down 'high-single digits' organically. This continued drag from the construction sector is offsetting gains in aerospace and water, keeping overall organic growth negative (-1%).
GAAP results show a loss of $(108)M due to separation costs, and the 'Continuing Operations' view complicates year-over-year comparisons. Relying heavily on 'Adjusted' metrics masks the cash costs of the recent restructuring.
⚖️ Verdict: ⚪
Neutral/Hold. DuPont executed well on what it controls (costs and margins), but the top line remains frozen by macro headwinds in construction. The 2026 guidance implies an acceleration that hasn't materialized yet in the order book.
Key Themes
Diversified Industrials Deceleration
The Diversified Industrials segment is struggling for volume. Organic sales fell 4% in Q4, deteriorating from the full-year average of -2%. While Aerospace remains a bright spot, the drag from 'ongoing weakness in construction markets' (Building Technologies down high-single digits) and printing/packaging is weighing heavily on the top line.
The Timing Shift Distortion
Q4 performance was artificially suppressed by a known 'order timing shift' related to the Qnity separation systems cut-over. Approximately $30 million of revenue (2% impact) was pulled forward into Q3. Without this anomaly, Healthcare & Water organic growth would have been stronger, and total company organic growth likely positive.
Operational Efficiency Driving Margins
Cost productivity is the standout positive. Consolidated Operating EBITDA margin expanded 80 bps to 24.2%. Most impressively, Diversified Industrials expanded margins by 110 bps to 22.6% despite the 4% drop in organic sales, showcasing strong pricing power and cost management.
GAAP Profitability Disconnect
While Adjusted EPS is up, GAAP Income from Continuing Operations was a loss of $(108) million (vs loss of $(291)M a year ago). This gap is driven by $228 million in separation-related costs and other payments. While treated as 'one-time,' these cash outflows impact the immediate balance sheet.
Other KPIs
Conversion rate of 118%. This metric excludes the heavy separation-related costs. However, GAAP Operating Cash Flow was only $87 million, reflecting the actual cash burden of the portfolio transformation.
Decelerating. Organic growth of +3% slowed from the full-year pace of +7%. While impacted by the $15M order timing shift, this segment is critical for the growth narrative and needs to re-accelerate to meet FY26 targets.
Improved significantly from $84 million in 24Q4. The cleaner balance sheet and debt paydowns post-separation are flowing through to the bottom line, supporting the 18% Adjusted EPS growth.
Guidance
Accelerating. The midpoint implies ~3.7% reported growth vs FY25. Management assumes ~3% organic growth, indicating they expect the construction headwinds to abate or be outpaced by Water/Healthcare growth.
Accelerating. Represents substantial growth (~35%) over FY25 Adjusted EPS of $1.68. This is driven by the full-year benefit of cost actions, lower interest expense, and the absence of separation noise.
Stable/Decelerating. Implies roughly flat sequential performance vs 25Q4 ($1.69B). Management assumes ~2% organic growth YoY, suggesting a slow start to the year before acceleration kicks in during H2.
Key Questions
Construction Recovery Timeline
With Building Technologies down high-single digits in Q4, what specific indicators underpin the assumption of ~3% total organic growth for FY26? Are you forecasting a construction rebound in H2?
Healthcare Deceleration
Healthcare & Water organic growth slowed from +7% FY to +3% Q4. Even adding back the 2% timing impact, growth is below the FY trend. Is this purely timing, or are we seeing demand fatigue in biopharma/medical packaging?
Capital Allocation Post-Spin
With the separation costs mostly settled and leverage low, when will the Board authorize a new share buyback program to utilize the improved free cash flow profile?